Tang Aijun, Kopeiková Pavla, Kopeckevá Jindrich
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112, USA.
Pharm Res. 2003 Mar;20(3):360-7. doi: 10.1023/a:1022639701388.
Studies on the recognition of epitopes presented on a template peptide showed the potential of nonapeptide-related sequences to act as biorecognition sites for the B-cell CD21 receptor. This study was intended to evaluate the capability of three epitope sequences to mediate specific cell binding and to enhance the cytotoxicity of HPMA copolymer conjugates.
HPMA copolymer conjugates were synthesized containing three different epitopes at various contents and either a fluorescent marker or doxorubicin (DOX). The binding and cytotoxicity of the conjugates to CD21+ Raji B cells and CD21- HSB-2 T cells were evaluated.
The epitope-containing conjugates were found to bind to Raji cells at different apparent affinities depending on epitope structure and content. The conjugates generally possessed higher affinities for Raji cells than for HSB-2 cells. Targeted HPMA copolymer-DOX conjugates exhibited higher cytotoxicities than the nontargeted conjugate, likely indicative of enhanced internalization by receptor-mediated endocytosis. HSB-2 cells were more sensitive to both free and polymer-bound DOX than Raji cells; however, the enhancement of cytotoxicity of the conjugates by incorporation of epitopes was more pronounced for Raji cells.
The results verified the concept of using receptor-binding epitopes as targeting moieties in HPMA copolymer conjugates for the delivery of anticancer drugs to lymphoma cells.
对模板肽上呈现的表位识别的研究表明,九肽相关序列有潜力作为B细胞CD21受体的生物识别位点。本研究旨在评估三种表位序列介导特异性细胞结合以及增强HPMA共聚物缀合物细胞毒性的能力。
合成了含有不同含量的三种不同表位以及荧光标记物或阿霉素(DOX)的HPMA共聚物缀合物。评估了这些缀合物对CD21+ Raji B细胞和CD21- HSB-2 T细胞的结合及细胞毒性。
发现含表位的缀合物根据表位结构和含量以不同的表观亲和力与Raji细胞结合。这些缀合物对Raji细胞的亲和力通常高于对HSB-2细胞的亲和力。靶向的HPMA共聚物-DOX缀合物比非靶向缀合物表现出更高的细胞毒性,这可能表明通过受体介导的内吞作用增强了内化。HSB-2细胞对游离和聚合物结合的DOX都比Raji细胞更敏感;然而,对于Raji细胞,通过掺入表位增强缀合物的细胞毒性更为明显。
结果证实了在HPMA共聚物缀合物中使用受体结合表位作为靶向部分将抗癌药物递送至淋巴瘤细胞这一概念。